Duan Yanli, Li Xiangyu, Han Song, Guan Jingwei, Chen Zhiying, Li Weili, Meng Ran, Ding Jiayue
Department of Neurology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Department of Neurology, Tianjin Huanhu Hospital, Tianjin, People's Republic of China.
Clin Interv Aging. 2025 Jul 2;20:969-981. doi: 10.2147/CIA.S521584. eCollection 2025.
Normobaric hyperoxia (NBO) is a standard oxygenation intervention for various conditions/diseases including stroke. The present review summarizes the current literature addressing the neuroprotective mechanisms of NBO in acute ischemic stroke (AIS), intracranial hemorrhage, and chronic cerebral ischemia, as well as its combination with other therapies to identify a more appropriate and effective NBO treatment method and to benefit more patients in clinical settings. The primary mechanism of action of NBO is the elevation of the interstitial partial pressure of oxygen in arterial blood (O) in brain tissue. NBO preconditioning yields moderate production of free radicals before AIS, which can increase antioxidant enzyme production, alter mitochondrial membrane lipids, increase tumor necrosis factor-alpha (TNF-α) converting enzyme levels, stimulate the hypoxia-inducible factor signaling pathway, upregulate glutamate transporters, Na-Ca exchanger, and the metabotropic glutamate receptor after AIS, thus conferring neuroprotection to brain tissue. NBO postconditioning benefits AIS by protecting the penumbra and extending the recanalization time window, indicating that reperfusion is critical for the beneficial effects of NBO. Some previous clinical trials have obtained negative results because they enrolled non-reperfused cohorts. Given penumbra protection, NBO can enhance the efficacy of recanalization therapy, including thrombolysis and endovascular treatment. Clinical studies have indicated that NBO benefits only patients with reperfusion, which is consistent with animal-based research. NBO combined with medications, such as ethanol, minocycline, and edaravone, can more effectively treat AIS than NBO alone. Moreover, NBO demonstrates promise for the treatment of intracranial hemorrhage and chronic cerebral ischemia. NBO is a safe and effective therapy for stroke; however, eligible populations should be restricted to those with penumbra or ischemic and hypoxic brain tissues.
常压高氧(NBO)是包括中风在内的各种病症/疾病的标准氧合干预措施。本综述总结了当前关于NBO在急性缺血性中风(AIS)、颅内出血和慢性脑缺血中的神经保护机制的文献,以及其与其他疗法的联合应用,以确定更合适、有效的NBO治疗方法,并使更多患者在临床环境中受益。NBO的主要作用机制是提高脑组织中动脉血氧的组织间分压(O)。NBO预处理在AIS之前产生适度的自由基,可增加抗氧化酶的产生,改变线粒体膜脂质,提高肿瘤坏死因子-α(TNF-α)转换酶水平,刺激缺氧诱导因子信号通路,在AIS后上调谷氨酸转运体、钠钙交换体和代谢型谷氨酸受体,从而为脑组织提供神经保护。NBO后处理通过保护半暗带和延长再灌注时间窗使AIS受益,这表明再灌注对于NBO的有益作用至关重要。一些先前的临床试验得出了阴性结果,因为他们纳入了未再灌注的队列。鉴于对半暗带的保护,NBO可增强再灌注治疗的疗效,包括溶栓和血管内治疗。临床研究表明,NBO仅对再灌注患者有益,这与基于动物的研究一致。NBO与乙醇、米诺环素和依达拉奉等药物联合使用,比单独使用NBO能更有效地治疗AIS。此外,NBO在治疗颅内出血和慢性脑缺血方面也显示出前景。NBO是一种安全有效的中风治疗方法;然而,符合条件的人群应限于有半暗带或缺血缺氧脑组织的患者。